Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TEOSYAL PureSense ULTRA DEEP is a sterile, transparent, viscoelastic dermal filler composed of cross-linked hyaluronic acid (25 mg/ml) and lidocaine (3 mg/ml). Manufactured by Teoxane Laboratories, it is specifically designed for deep dermal or subcutaneous injection to restore facial volume, resculpt contours (such as cheeks and chin), and correct deep wrinkles or minor ptosis. The hyaluronic acid component acts by binding water to provide structural volume, while the lidocaine serves as a local anesthetic to minimize discomfort during the procedure. The product is CE-marked for use in Europe but has not received FDA approval in the United States.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TEOSYAL PureSense ULTRA DEEP.